12/17
08:14 am
apre
Aprea Therapeutics, Inc. (NASDAQ: APRE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Medium
Report
Aprea Therapeutics, Inc. (NASDAQ: APRE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
12/11
08:33 am
apre
Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward [Yahoo! Finance]
Low
Report
Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward [Yahoo! Finance]
12/11
08:30 am
apre
Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward
Medium
Report
Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward
11/18
08:07 am
apre
Aprea Therapeutics, Inc. (NASDAQ: APRE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
High
Report
Aprea Therapeutics, Inc. (NASDAQ: APRE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
11/13
11:16 am
apre
Here's Why Aprea Therapeutics (APRE) Could be Great Choice for a Bottom Fisher [Yahoo! Finance]
Low
Report
Here's Why Aprea Therapeutics (APRE) Could be Great Choice for a Bottom Fisher [Yahoo! Finance]
11/10
09:02 am
apre
Aprea Therapeutics Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
Low
Report
Aprea Therapeutics Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
11/7
10:32 am
apre
Aprea Therapeutics, Inc. (APRE) Reports Q3 Loss, Lags Revenue Estimates [Yahoo! Finance]
Low
Report
Aprea Therapeutics, Inc. (APRE) Reports Q3 Loss, Lags Revenue Estimates [Yahoo! Finance]
11/7
08:00 am
apre
Aprea Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Low
Report
Aprea Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
10/24
08:08 am
apre
Aprea Therapeutics, Inc. (NASDAQ: APRE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Neutral
Report
Aprea Therapeutics, Inc. (NASDAQ: APRE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
10/23
03:10 pm
apre
Insider Spends US$132k Buying More Shares In Aprea Therapeutics [Yahoo! Finance]
Low
Report
Insider Spends US$132k Buying More Shares In Aprea Therapeutics [Yahoo! Finance]
10/23
08:30 am
apre
Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics
Neutral
Report
Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics
10/14
08:30 am
apre
Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit
Low
Report
Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit
10/10
08:30 am
apre
Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics
Low
Report
Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics
10/9
08:30 am
apre
Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development
Medium
Report
Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development
10/1
08:30 am
apre
Halda Therapeutics Appoints Veteran Biopharma Leader, Christian Schade, as President and Chief Executive Officer
Medium
Report
Halda Therapeutics Appoints Veteran Biopharma Leader, Christian Schade, as President and Chief Executive Officer